Why the study?
Does CABG improve clinical outcomes compared to PCI in diabetic patients with multivessel coronary artery disease?
Does CABG improve clinical outcomes compared to PCI in diabetic patients with multivessel coronary artery disease?
This review reinforces that CABG remains the standard of care over PCI for diabetic patients with multivessel coronary artery disease due to better long-term survival and lower rates of myocardial infarction.
Supports CABG preference in diabetic multivessel CAD; leaves open impact of newest stents in updated trials.
Surgical coronary revascularization and percutaneous coronary intervention were demonstrated to be effective treatments for coronary artery disease. However, the optimal revascularization strategy remains unclear in certain patient subsets. The recently published Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial is a randomized study evaluating the use of CABG versus PCI in diabetic patients with multivessel coronary disease. The purpose of this study was to review the available literature based on randomized trials and observational studies in order to allow clinicians to make evidence-based decisions when treating diabetic patients with multivessel coronary disease. The current evidence suggests that CABG should remain the standard of care for this patient population.
No takes yet. Share an insight, caveat, or question.
Nicolini et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: